Scarica l'app Stockscreener
138.59
4.34%
-6.285
Dopo l'orario di chiusura:
139.47
0.875
+0.63%
Precedente Chiudi:
$144.88
Aprire:
$146
Volume 24 ore:
732.37K
Relative Volume:
0.87
Capitalizzazione di mercato:
$8.97B
Reddito:
$74.06M
Utile/perdita netta:
$-114.71M
Rapporto P/E:
-76.83
EPS:
-1.8039
Flusso di cassa netto:
$-117.90M
1 W Prestazione:
-0.07%
1M Prestazione:
-6.47%
6M Prestazione:
+42.05%
1 anno Prestazione:
+75.06%
Intervallo 1D:
$137.81
$146.00
Intervallo di 1 settimana:
$137.25
$152.19
Portata 52W:
$65.75
$160.81
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Nome
Protagonist Therapeutics Inc
Settore
Industria
Telefono
(510) 474-0170
Indirizzo
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
138.59 | 8.97B | 74.06M | -114.71M | -117.90M | -1.8039 |
VRTX
Vertex Pharmaceuticals Inc
|
485.17 | 122.97B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
214.50 | 85.64B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.52 | 77.58B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
803.74 | 50.54B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.35 | 40.37B | 742.00K | -1.37B | -1.07B | -7.0731 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-08-10 | Aggiornamento | Goldman | Neutral → Buy |
| 2026-05-21 | Iniziato | Wolfe Research | Outperform |
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-09-12 | Iniziato | Leerink Partners | Outperform |
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-12-06 | Iniziato | Goldman | Neutral |
| 2024-11-05 | Iniziato | Wedbush | Outperform |
| 2024-09-24 | Iniziato | TD Cowen | Buy |
| 2024-09-09 | Iniziato | Truist | Buy |
| 2023-10-30 | Iniziato | CapitalOne | Overweight |
| 2023-05-25 | Ripresa | Jefferies | Buy |
| 2022-08-25 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-02-11 | Iniziato | BTIG Research | Buy |
| 2021-10-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-10-11 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-05-24 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-05-24 | Iniziato | Northland Capital | Outperform |
| 2021-01-06 | Iniziato | JP Morgan | Overweight |
| 2020-12-16 | Iniziato | Piper Sandler | Overweight |
| 2020-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-15 | Iniziato | Jefferies | Buy |
| 2020-05-18 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-08 | Iniziato | H.C. Wainwright | Buy |
| 2019-05-09 | Aggiornamento | Stifel | Hold → Buy |
| 2018-12-06 | Iniziato | Nomura | Buy |
| 2018-01-29 | Iniziato | Stifel | Buy |
| 2017-07-21 | Iniziato | BTIG Research | Buy |
Mostra tutto
Protagonist Therapeutics Inc Borsa (PTGX) Ultime notizie
Protagonist Therapeutics, Inc. (PTGX) Stock Forecasts - Yahoo Finance
Protagonist Therapeutics, Inc. (PTGX) Options Chain - Yahoo! Finance Canada
Protagonist Therapeutics, Inc. (PTGX) Options Chain - Yahoo! Finance Canada
Protagonist Therapeutics, Inc. (PTGX) options chain - Yahoo Finance Australia
Protagonist Therapeutics(PTGX.US) Officer Sells US$8.31 Million in Common Stock - Moomoo
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) CFO Sells 58,629 Shares of Company Stock - MarketBeat
After exercising options, Protagonist Therapeutics (PTGX) CFO sells 58,629 shares under a trading plan. - stocktitan.net
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Has Consensus Price Target of $147.13 According to Analysts - MarketBeat
Protagonist Therapeutics, Inc. (PTGX) Stock Forecasts - Yahoo Finance
Form 144 PROTAGONIST THERAPEUTICS For: 1 October By Investing.com - Investing.com Nigeria
Officer Asif Ali plans to sell 58,629 Protagonist Therapeutics (PTGX) shares. - Stock Titan
Here's How Much $100 Invested In Protagonist Therapeutics 10 Years Ago Would Be Worth Today - Benzinga
Protagonist Therapeutics (NASDAQ:PTGX) Shares Gap UpWhat's Next? - MarketBeat
Top Generate Biomedicines (GENB) Competitors 2026 - MarketBeat
Protagonist Therapeutics (Nasdaq:PTGX)Stock Analysis - simplywall.st
1,324,498 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Bank of America Corp DE - MarketBeat
PTGX: Protagonist Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Protagonist Therapeutics (NASDAQ:PTGX) Combines High Growth Momentum With a Breakout Setup - ChartMill
VIRGINIA RETIREMENT SYSTEMS ET Al Buys Shares of 11,200 Protagonist Therapeutics, Inc. $PTGX - MarketBeat
(PTGX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Protagonist Therapeutics CEO sells $18.2m in shares By Investing.com - Investing.com Australia
Hsbc Holdings PLC Purchases 24,045 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics Insider Sold Shares Worth $18,240,568, According to a Recent SEC Filing - Yahoo Finance
Dinesh Ph Patel Sells 63,548 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock - MarketBeat
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells 54,174 Shares - MarketBeat
Protagonist Therapeutics CEO sells $18.2m in shares - Investing.com India
Protagonist Therapeutics CEO sells $18.2m in shares By Investing.com - Investing.com UK
Protagonist Therapeutics (PTGX) CEO sells 125K shares in preset plan - Stock Titan
Protagonist Therapeutics(PTGX.US) Officer Sells US$18.24 Million in Common Stock - Moomoo
Protagonist Therapeutics at Cantor conference: cash, launches and pipeline By Investing.com - Investing.com Nigeria
Protagonist Therapeutics at Cantor conference: cash, launches and pipeline By Investing.com - Investing.com UK
Protagonist Therapeutics, Inc. at Citi Biopharma Back to School Summit Transcript - GuruFocus
Transcript : Protagonist Therapeutics, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 10 - marketscreener.com
Protagonist Therapeutics authorizes $300 million buyback plan By Investing.com - Investing.com Nigeria
Protagonist Therapeutics authorizes $300 million buyback plan By Investing.com - Investing.com South Africa
Protagonist Therapeutics (PTGX) CEO gifts stock to family - Stock Titan
Protagonist Therapeutics authorizes $300 million buyback plan - investing.com
Protagonist Therapeutics Announces $300 Million Share Repurchase Program - ACCESS Newswire
Protagonist Therapeutics Announces $300 Million Share Repurchase Program - chronicle-tribune.com
Protagonist Therapeutics Announces $300 Million Share Repurchase Program - marketscreener.com
News by ACCESS Newswire on TradingView, 2026-09-08 - TradingView
Up to $300 million could go toward buying back shares at Protagonist Therapeutics. - Stock Titan
Protagonist Therapeutics Announces $300 Million Share Repurchase Program - Yahoo Finance
Protagonist Therapeutics (PTGX) 10K Form and Latest SEC Filings 2026 - MarketBeat
Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight - GlobeNewswire Inc.
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Protagonist (PTGX) Swings To A Profit As Two Drugs Near Blockbuster Status - Yahoo Finance
MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model? - Yahoo Finance
Protagonist Therapeutics (PTGX) Stock Looks Fully Priced After Its 7x Run - simplywall.st
Research Analysts Offer Predictions for PTGX Q1 Earnings - marketbeat.com
Protagonist Therapeutics Inc Azioni (PTGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Protagonist Therapeutics Inc Azioni (PTGX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ASIF ALI | Officer |
Sep 30 '26 |
Proposed Sale |
140.97 |
58,629 |
8,264,930 |
0 |
| Ali Asif | Chief Financial Officer |
Sep 30 '26 |
Sale |
141.78 |
58,629 |
8,312,294 |
59,003 |
| PATEL DINESH V PH D | President and CEO |
Sep 10 '26 |
Sale |
144.10 |
7,278 |
1,048,760 |
522,968 |
| PATEL DINESH V PH D | President and CEO |
Sep 10 '26 |
Option Exercise |
21.58 |
7,278 |
157,059 |
530,246 |
| PATEL DINESH V PH D | President and CEO |
Sep 09 '26 |
Option Exercise |
21.58 |
63,548 |
1,371,366 |
586,516 |
| PATEL DINESH V PH D | President and CEO |
Sep 09 '26 |
Sale |
146.18 |
63,548 |
9,289,447 |
522,968 |
| PATEL DINESH V PH D | President and CEO |
Sep 08 '26 |
Sale |
145.87 |
54,174 |
7,902,361 |
522,968 |
| PATEL DINESH V PH D | President and CEO |
Sep 08 '26 |
Option Exercise |
21.58 |
54,174 |
1,169,075 |
577,142 |
| PATEL DINESH V PH D | President and CEO |
Aug 11 '26 |
Sale |
148.52 |
34,239 |
5,085,176 |
523,478 |
| PATEL DINESH V PH D | President and CEO |
Aug 11 '26 |
Option Exercise |
21.58 |
34,239 |
738,878 |
557,717 |
4.75%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):